Wockhardt receives USFDA QIDP status for WCK 6777

Wockhardt announced that the company has received qualified infectious disease product (QIDP) designation for WCK 6777 from United States Food & Drug Administration (USFDA). WCK 6777 is once-a-day combination antibiotic of β-lactam enhancer.

WCK 6777 is based on Wockhardt’s NCE Zidebactam. It overcomes various problematic bacterial resistance mechanisms such as metallo-β-lactamases, etc. and also the ability to overpower other tough resistance mechanisms such as reduced drug uptake and drug efflux encountered in contemporary multidrug (MDR) resistant Gram-negative pathogens. It is expected to be the first-ever antibiotic facilitating the treatment of MDR infections in out-patient settings. It is used for the treatment of complicated urinary tract infections, including pyelonephritis (cUTI) and also of complicated intra-abdominal infections (cIAI). The company intends to work for the global development of WCK 6777, covering important markets of US, Europe, China and India.

Wockhardt is a research-based global pharmaceutical and biotech company. Wockhardt's new drug discovery programme has focussed on unmet need of anti-bacterial drugs that are effective against the menace of untreatable superbugs.

On Monday, the stock of the company closed at Rs 263.90, down by 2.53 per cent or Rs 6.85 per share. The 52-week high is Rs 440.50 and 52-week low is Rs 147.20 on BSE.